Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
VRTX Vertex $170.08 -3.27 (-1.89%) 08:32 12/17/18 12/17 08:32 12/17/18 08:32 Hot Stocks	Vertex CFO Thomas Graney resigned last week with immediate effect » Vertex Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Thursday
VRTX Vertex $171.99 -3.56 (-2.03%) 12:20 12/13/18 12/13 12:20 12/13/18 12:20 Options	Sudden burst of activity in Vertex Pharma weekly calls » Sudden burst of activity… Sudden burst of activity in Vertex Pharma weekly calls. The stock down 1.5% to $172.88 and Jan 11th 210 calls trade in small lots for 25 to 30c. Then Dec 28th 200 calls for 29 and 30c. More than 1.5K trade in both strikes. 560 Dec 28th 197.5 calls also changed hands. Overall volume 2X daily average at 4.1K calls and just 90 puts. The interest in 12/28 and 1/11 upside calls seems to express expectations for a run higher in shares in the weeks ahead and comes after several months of seesaw action - the stock at the same levels today as nine months ago. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
VRTX Vertex $175.55 2.23 (1.29%) 08:09 12/13/18 12/13 08:09 12/13/18 08:09 Hot Stocks	Vertex granted Market Authorization for ORKAMBI in Canada » Vertex Pharmaceuticals… Vertex Pharmaceuticals announced that Health Canada has granted Market Authorization for ORKAMBI to include use in children ages 2 through 5 years with cystic fibrosis who have two copies of the F508del CFTR mutation. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
CRSP Crispr Therapeutics $38.71 1.01 (2.68%) , VRTX Vertex $179.48 1.08 (0.61%) 07:10 11/30/18 11/30 07:10 11/30/18 07:10 Initiation	Crispr Therapeutics, Vertex initiated at Needham » Crispr Therapeutics… Crispr Therapeutics initiated with a Buy at Needham. Needham analyst Alan Carr initiated CRISPR Therapeutics (CRSP) with a Buy rating and a price target of $62 based on its position as a "leader in gene editing". The analyst notes that the company is "initially focused on ex vivo applications of the technology associated with reduced technical and safety risks", which he believes to hold "substantial value, particularly in immuno-oncology." Carr adds that with Crispr and collaborator Vertex (VRTX) recently launching a clinical development of CTX-001 in Beta Thalassemia and Sickle Cell Disease, he estimates the company to launch these products in the U.S. in 2022 and 2023, respectively. CRSP Crispr Therapeutics $38.71 1.01 (2.68%) VRTX Vertex $179.48 1.08 (0.61%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
VRTX Vertex $178.40 2.95 (1.68%) 05:29 11/29/18 11/29 05:29 11/29/18 05:29 Hot Stocks	Vertex announces EC approval for Kalydeco » Vertex Pharmaceuticals… Vertex Pharmaceuticals announced that the European Commission has granted approval of the label extension for Kalydeco to include the treatment of people with cystic fibrosis aged 12 to less than24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

UTX United Technologies $122.62 -5.37 (-4.20%) , GM General Motors $36.70 -0.945 (-2.51%) … 16:17 11/27/18 11/27 16:17 11/27/18 16:17 On The Fly	Fly Intel: Wall Street's top stories for Tuesday » Stocks opened sharply… Open Full Text UTX United Technologies $122.62 -5.37 (-4.20%) GM General Motors $36.70 -0.945 (-2.51%) AAPL Apple $174.23 -0.39 (-0.22%) AMZN Amazon.com $1,582.00 (0.00%) EBAY eBay $28.74 -0.06 (-0.21%) WMT Walmart $95.05 -0.08 (-0.08%) TGT Target $71.38 2.14 (3.09%) M Macy's $33.89 1.34 (4.12%) BBY Best Buy $64.68 0.3 (0.47%) SAVE Spirit Airlines $58.74 7.76 (15.22%) VRTX Vertex $175.45 8.08 (4.83%) PZZA Papa John's $51.79 -5.88 (-10.20%) GTHX G1 Therapeutics $35.45 -4.48 (-11.22%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Nov 27 Nov 27 Nov 27 Nov 28 Nov 29 Nov 04 Dec 04 Dec 05 Dec 03 Mar
VRTX Vertex $175.23 7.86 (4.70%) 11:11 11/27/18 11/27 11:11 11/27/18 11:11 Recommendations	Vertex analyst commentary at Piper Jaffray » Piper says Vertex's… Piper says Vertex's VX-659 achieved 'unprecedented' improvement in trials. After Vertex announced 4-week efficacy and 12-week safety data from two TripleRx Phase 3 trials of VX-659 plus Symdeko, Piper Jaffray analyst Edward Tenthoff said VX-659 achieved "unprecedented" four-week mean absolute improvement in ppFEV1 in both patient populations studied. He anticipates Vertex will file an NDA on the best TripleRx regimen in mid 2019 and currently sees the first TripleRx reaching the market in 2020. Tenthoff keeps an Overweight rating and $217 price target on Vertex shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
VRTX Vertex $172.40 5.03 (3.01%) , TSCO Tractor Supply $90.60 1.76 (1.98%) … 09:55 11/27/18 11/27 09:55 11/27/18 09:55 Options	Early notable gainers among liquid option names on November 27th » Notable gainers among… Notable gainers among liquid option names this morning include Vertex (VRTX) $174.64 +7.27, Tractor Supply (TSCO) $91.17 +2.35, Delta Air Lines (DAL) $57.99 +1.31, First Solar (FSLR) $44.33 +0.91, and Southwest (LUV) $53.63 +0.88. VRTX Vertex $172.40 5.03 (3.01%) TSCO Tractor Supply $90.60 1.76 (1.98%) DAL Delta Air Lines $58.31 1.62 (2.86%) FSLR First Solar $43.61 0.18 (0.41%) LUV Southwest $53.67 0.92 (1.74%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
VRTX Vertex $167.37 6.95 (4.33%) 08:12 11/27/18 11/27 08:12 11/27/18 08:12 Hot Stocks	Vertex says two CF Phase 3 studies met primary endpoints » Vertex Pharmaceuticals… Vertex Pharmaceuticals announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two Phase 3 studies in people with cystic fibrosis, or CF. Data from a pre-specified interim analysis of the Phase 3 study in people with one F508del mutation and one minimal function mutation showed a mean absolute improvement in ppFEV1 of 14.0 percentage points from baseline at week 4 of treatment compared to placebo. In the Phase 3 study in people with two F508del mutations, the addition of VX-659 in patients already receiving tezacaftor and ivacaftor resulted in a mean absolute improvement in ppFEV1 of 10.0 percentage points from baseline at week 4 of treatment compared to the control group in whom placebo was added to tezacaftor and ivacaftor. The VX-659 triple combination regimen was generally well tolerated, and the safety and efficacy profile from the results released today supports the potential submission of a New Drug Application for the VX-659 triple combination regimen. Vertex also announced that enrollment is complete for the two Phase 3 studies of the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor in people with CF with one F508del mutation and one minimal function mutation and in people with two F508del mutations. Vertex remains on track to report topline data from both Phase 3 studies of the VX-445 triple combination regimen in the first quarter of 2019. The data expected in the first quarter of 2019 for VX-445 and the data reported today for VX-659 will enable Vertex to choose the best regimen to submit for potential regulatory approvals globally and will provide the basis for potential submission of an NDA for a triple combination regimen to the FDA no later than mid-2019. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
WYNN Wynn Resorts $108.64 4.31 (4.13%) , FTI TechnipFMC $23.43 0.81 (3.58%) … 09:55 11/26/18 11/26 09:55 11/26/18 09:55 Options	Early notable gainers among liquid option names on November 26th » Notable gainers among… Notable gainers among liquid option names this morning include Wynn Resorts (WYNN) $109.44 +5.11, FMC Technologies (FTI) $23.67 +1.05, Newell Brands (NWL) $22.65 +0.91, Vertex (VRTX) $167.07 +6.67, and CVS Health (CVS) $78.18 +3.02. WYNN Wynn Resorts $108.64 4.31 (4.13%) FTI TechnipFMC $23.43 0.81 (3.58%) NWL Newell Brands $22.34 0.6 (2.76%) VRTX Vertex $165.62 5.2 (3.24%) CVS CVS Health $77.61 2.1301 (2.82%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Nov 28 Nov

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial